Generic placeholder image

Current Drug Discovery Technologies

Editor-in-Chief

ISSN (Print): 1570-1638
ISSN (Online): 1875-6220

Research Article

Exploration of Novel PDEδ Inhibitor Based on Pharmacophore and Molecular Docking against KRAS Mutant in Colorectal Cancer

Author(s): Mohammed Mouhcine, Youness Kadil*, Imane Rahmoune and Houda Filali

Volume 20, Issue 4, 2023

Published on: 12 May, 2023

Article ID: e160423215830 Pages: 10

DOI: 10.2174/1570163820666230416152843

Price: $65

Abstract

Aim: The prenyl-binding protein, phosphodiesterase-δ (PDEδ), is essential for the localization of prenylated KRas to the plasma membrane for its signaling in cancer.

Introduction: The general objective of this work was to develop virtually new potential inhibitors of the PDEδ protein that prevent Ras enrichment at the plasma membrane.

Methods: All computational molecular modeling studies were performed by Molecular Operating Environment (MOE). In this study, sixteen crystal structures of PDEδ in complex with fifteen different fragment inhibitors were used in the protein-ligand interaction fingerprints (PLIF) study to identify the chemical features responsible for the inhibition of the PDEδ protein. Based on these chemical characteristics, a pharmacophore with representative characteristics was obtained for screening the BindingDB database. Compounds that matched the pharmacophore model were filtered by the Lipinski filter. The ADMET properties of the compounds that passed the Lipinski filter were predicted by the Swiss ADME webserver and by the ProTox-II-Prediction of Toxicity of Chemicals web server. The selected compounds were subjected to a molecular docking study.

Results: In the PLIF study, it was shown that the fifteen inhibitors formed interactions with residues Met20, Trp32, Ile53, Cys56, Lys57, Arg61, Gln78, Val80, Glu88, Ile109, Ala11, Met117, Met118, Ile129, Thr131, and Tyr149 of the prenyl-binding pocket of PDEδ. Based on these chemical features, a pharmacophore with representative characteristics was composed of three bond acceptors, two hydrophobic elements, and one hydrogen bond donor. When the pharmacophore model was used in the virtual screening of the Binding DB database, 2532 compounds were selected. Then, the 2532 compounds were screened by the Lipinski rule filter. Among the 2532 compounds, two compounds met the Lipinski's rule. Subsequently, a comparison of the ADMET properties and the drug properties of the two compounds was performed. Finally, compound 2 was selected for molecular docking analysis and as a potential inhibitor against PDEδ.

Conclusion: The hit found by the combination of structure-based pharmacophore generation, pharmacophore- based virtual screening, and molecular docking showed interaction with key amino acids in the hydrophobic pocket of PDEδ, leading to the discovery of a novel scaffold as a potential inhibitor of PDEδ.

Keywords: Colorectal cancer, structure-based pharmacophore, molecular docking, KRAS, PDEδ inhibitors, chemical features.

Graphical Abstract
[1]
Bos JL. ras oncogenes in human cancer: A review. Cancer Res 1989; 49(17): 4682-9.
[PMID: 2547513]
[2]
Liu P, Wang Y, Li X, et al. Targeting the untargetable KRAS in cancer therapy. Acta Pharm Sin B 2019; 9(5): 871-9.
[http://dx.doi.org/10.1016/j.apsb.2019.03.002] [PMID: 31649840]
[3]
Abrams SI, Hand PH, Tsang KY, et al. Mutant ras epitopes as targets for cancer vaccines. Semin Oncol 1996; 23(1): 118-34.
[PMID: 8607022]
[4]
Nussinov R, Tsai CJ, Jang H, et al. Does ras activate raf and PI3K allosterically? Front Oncol 2019; 9(November): 1231.
[http://dx.doi.org/10.3389/fonc.2019.01231] [PMID: 31799192]
[5]
Ahearn I, Zhou M, Philips MR, et al. Posttranslational modifications of RAS proteins. Cold Spring Harb Perspect Med 2018; 8(11): a031484.
[http://dx.doi.org/10.1101/cshperspect.a031484]
[6]
Dong Z, Kong L, Wan Z, et al. Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients. Sci Rep 2019; 9(1): 16894.
[http://dx.doi.org/10.1038/s41598-019-53039-y] [PMID: 31729406]
[7]
Bhullar DS, Barriuso J, Mullamitha S, et al. Biomarker concordance between primary colorectal cancer and its metastases. EBio Med 2019; 40: 363-74.
[http://dx.doi.org/10.1016/j.ebiom.2019.01.050] [PMID: 30733075]
[8]
Dolatkhah R, Somi MH, Shabanloei R, et al. Main risk factors association with proto-oncogene mutations in colorectal cancer. Asian Pac J Cancer Prev 2018; 19(8): 2183-90.
[http://dx.doi.org/10.22034/APJCP.2018.19.8.2183] [PMID: 30139223]
[9]
Gysin S, Salt M, Young A, et al. Therapeutic strategies for targeting RAS proteins. Genes Cancer 2011; 2(3): 359-72.
[http://dx.doi.org/10.1177/1947601911412376] [PMID: 21779505]
[10]
Hancock JF, Paterson H, Marshall CJ, et al. A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21RAS to the plasma membrane. Cell 1990; 63(1): 133-9.
[http://dx.doi.org/10.1016/0092-8674(90)90294-O] [PMID: 2208277]
[11]
Avery MA, Weldon DJ, Muraleedharan KM, et al. Drugs for parasitic infections: Advances in the discovery of new antimalarials Reference module in chemistry, molecular sciences and chemical engineering. Elsevier 2016.
[http://dx.doi.org/10.1016/B978-0-12-409547-2.11056-X]
[12]
Costa CB, Casalta-Lopes J, Andrade C, et al. Farnesyltransferase inhibitors: Molecular evidence of therapeutic efficacy in acute lymphoblastic leukemia through cyclin D1 inhibition. Anticancer Res 2012; 32(3): 831-8.
[PMID: 22399601]
[13]
Christiansen JR, Kolandaivelu S, Bergo MO, et al. RAS-converting enzyme 1-mediated endoproteolysis is required for trafficking of rod phosphodiesterase 6 to photoreceptor outer segments. Proc Natl Acad Sci 2011; 108(21): 8862-6.
[http://dx.doi.org/10.1073/pnas.1103627108] [PMID: 21555557]
[14]
Zimmermann G, Papke B, Ismail S, et al. Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling. Nature 2013; 497(7451): 638-42.
[http://dx.doi.org/10.1038/nature12205]
[15]
Martín-Gago P, Fansa EK, Klein CH, et al. A PDE6δ-KRas inhibitor chemotype with up to seven H-bonds and picomolar affinity that prevents efficient inhibitor release by Arl2. Angew Chem Int Ed 2017; 56(9): 2423-8.
[http://dx.doi.org/10.1002/anie.201610957] [PMID: 28106325]
[16]
Liu T, Lin Y, Wen X, et al. A web-accessible database of experimentally determined protein-ligand binding affinities. Nucleic Acids Res 2007; 35(S1): 198-201.
[http://dx.doi.org/10.1093/nar/gkl999]
[17]
Molecular Operating Environment (MOE), 2019.01; Chemical Computing Group ULC, 1010 Sherbooke St. West, Suite #910, Montreal, QC, Canada, H3A 2R7. 2021. 2007 Available from: https://www.chemcomp.com/Products.htm
[18]
Lipinski CA, Lombardo F, Dominy BW, et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46(1-3): 3-26.
[http://dx.doi.org/10.1016/S0169-409X(00)00129-0] [PMID: 11259830]
[19]
Daina A, Michielin O, Zoete V, et al. A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017; 7(1): 42717.
[http://dx.doi.org/10.1038/srep42717] [PMID: 28256516]
[20]
Banerjee P, Eckert AO, Schrey AK, et al. A webserver for the prediction of toxicity of chemicals. Nucleic Acids Res 2018; 46(W1): W257-63.
[http://dx.doi.org/10.1093/nar/gky318] [PMID: 29718510]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy